This is a summary of the European public assessment report (EPAR) for Duavive. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Duavive. For practical information about using Duavive, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Duavive is indicated for: - Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. The experience treating women older than 65 years is limited.
Therapeutic Area (MeSH)
N/AATC Code
G03CC07
ATC Item
conjugated estrogens and bazedoxifene
Pharmacotherapeutic Group
conjugated estrogens and bazedoxifene
Active Substance (Summary)
N/AINN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| oestrogens conjugated | N/A | Estrogens Conjugated/Meprobamate |
| bazedoxifene | N/A | 巴多昔芬 |
EMA Name
Duavive
Medicine Name
Duavive
Aliases
N/ANo risk management plan link.
